Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2000 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/26254 http://dx.doi.org/10.1093/jac/45.3.295 |
Resumo: | The potency and spectrum of various antimicrobial agents tested against 434 bacterial isolates causing urinary tract infection (UTI) in hospitalized patients in Latin America were evaluated. the genotypes of the extended-spectrum beta-lactamase-producing and selected multi-resistant isolates were also evaluated by molecular typing techniques. Escherichia coli (60.4%) was the most common aetiological agent causing UTI, followed by Klebsiella spp. (11.2%) and Pseudomonas aeruginosa (8.3%). in contrast, Enterococcus spp. isolates caused only 2.3% of UTIs. Fewer than 50% of E. coli isolates were susceptible to broad-spectrum penicillins. the resistance rates to ciprofloxacin and the new quinolones were also high among these isolates. the molecular characterization of ciprofloxacin-resistant E coli showed that most of them have a double mutation in the gyrA gene associated with a single mutation in the parC gene. the Klebsiella pneumoniae isolates studied demonstrated high resistance rates to beta-lactam drugs, including broad-spectrum cephalosporins. the carbapenems were the compounds with the highest susceptibility rate among these isolates (100.0% susceptible) followed by cefepime (91.7% susceptible). Meropenem, imipenem and cefepime were also the most active drugs against Enterobacter spp. Among P. aeruginosa isolates, meropenem (MIC50, 2 mg/L) was the most active compound, followed by imipenem (MIC50, 4 mg/L), cefepime (MIC50, 8 mg/L) end ceftazidime (MIC50, 16 mg/L). the results presented in this report confirm that bacterial resistance continues to be a great problem in Latin American medical institutions. |
id |
UFSP_513a6f06af13c46a0525b83ebd9af4e4 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/26254 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Gales, Ana C. [UNIFESP]Jones, R. N.Gordon, K. A.Sader, Helio S. [UNIFESP]Wilke, W. W.Beach, M. L.Pfaller, M. A.Doern, G. V.SENTRY Study Grp Latin AmerUniv IowaUniversidade Federal de São Paulo (UNIFESP)2016-01-24T12:31:01Z2016-01-24T12:31:01Z2000-03-01Journal of Antimicrobial Chemotherapy. Oxford: Oxford Univ Press, v. 45, n. 3, p. 295-303, 2000.0305-7453http://repositorio.unifesp.br/handle/11600/26254http://dx.doi.org/10.1093/jac/45.3.29510.1093/jac/45.3.295WOS:000086244100005The potency and spectrum of various antimicrobial agents tested against 434 bacterial isolates causing urinary tract infection (UTI) in hospitalized patients in Latin America were evaluated. the genotypes of the extended-spectrum beta-lactamase-producing and selected multi-resistant isolates were also evaluated by molecular typing techniques. Escherichia coli (60.4%) was the most common aetiological agent causing UTI, followed by Klebsiella spp. (11.2%) and Pseudomonas aeruginosa (8.3%). in contrast, Enterococcus spp. isolates caused only 2.3% of UTIs. Fewer than 50% of E. coli isolates were susceptible to broad-spectrum penicillins. the resistance rates to ciprofloxacin and the new quinolones were also high among these isolates. the molecular characterization of ciprofloxacin-resistant E coli showed that most of them have a double mutation in the gyrA gene associated with a single mutation in the parC gene. the Klebsiella pneumoniae isolates studied demonstrated high resistance rates to beta-lactam drugs, including broad-spectrum cephalosporins. the carbapenems were the compounds with the highest susceptibility rate among these isolates (100.0% susceptible) followed by cefepime (91.7% susceptible). Meropenem, imipenem and cefepime were also the most active drugs against Enterobacter spp. Among P. aeruginosa isolates, meropenem (MIC50, 2 mg/L) was the most active compound, followed by imipenem (MIC50, 4 mg/L), cefepime (MIC50, 8 mg/L) end ceftazidime (MIC50, 16 mg/L). the results presented in this report confirm that bacterial resistance continues to be a great problem in Latin American medical institutions.Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USAUniversidade Federal de São Paulo, Lab Especial Microbiol, Div Infect Dis, São Paulo, BrazilUniversidade Federal de São Paulo, Lab Especial Microbiol, Div Infect Dis, São Paulo, BrazilWeb of Science295-303engOxford Univ PressJournal of Antimicrobial Chemotherapyhttp://www.oxfordjournals.org/access_purchase/self-archiving_policyb.htmlinfo:eu-repo/semantics/openAccessActivity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998)info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlereponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/262542023-01-12 21:52:29.007metadata only accessoai:repositorio.unifesp.br:11600/26254Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-01-13T00:52:29Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) |
title |
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) |
spellingShingle |
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) Gales, Ana C. [UNIFESP] |
title_short |
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) |
title_full |
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) |
title_fullStr |
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) |
title_full_unstemmed |
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) |
title_sort |
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) |
author |
Gales, Ana C. [UNIFESP] |
author_facet |
Gales, Ana C. [UNIFESP] Jones, R. N. Gordon, K. A. Sader, Helio S. [UNIFESP] Wilke, W. W. Beach, M. L. Pfaller, M. A. Doern, G. V. SENTRY Study Grp Latin Amer |
author_role |
author |
author2 |
Jones, R. N. Gordon, K. A. Sader, Helio S. [UNIFESP] Wilke, W. W. Beach, M. L. Pfaller, M. A. Doern, G. V. SENTRY Study Grp Latin Amer |
author2_role |
author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Univ Iowa Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Gales, Ana C. [UNIFESP] Jones, R. N. Gordon, K. A. Sader, Helio S. [UNIFESP] Wilke, W. W. Beach, M. L. Pfaller, M. A. Doern, G. V. SENTRY Study Grp Latin Amer |
description |
The potency and spectrum of various antimicrobial agents tested against 434 bacterial isolates causing urinary tract infection (UTI) in hospitalized patients in Latin America were evaluated. the genotypes of the extended-spectrum beta-lactamase-producing and selected multi-resistant isolates were also evaluated by molecular typing techniques. Escherichia coli (60.4%) was the most common aetiological agent causing UTI, followed by Klebsiella spp. (11.2%) and Pseudomonas aeruginosa (8.3%). in contrast, Enterococcus spp. isolates caused only 2.3% of UTIs. Fewer than 50% of E. coli isolates were susceptible to broad-spectrum penicillins. the resistance rates to ciprofloxacin and the new quinolones were also high among these isolates. the molecular characterization of ciprofloxacin-resistant E coli showed that most of them have a double mutation in the gyrA gene associated with a single mutation in the parC gene. the Klebsiella pneumoniae isolates studied demonstrated high resistance rates to beta-lactam drugs, including broad-spectrum cephalosporins. the carbapenems were the compounds with the highest susceptibility rate among these isolates (100.0% susceptible) followed by cefepime (91.7% susceptible). Meropenem, imipenem and cefepime were also the most active drugs against Enterobacter spp. Among P. aeruginosa isolates, meropenem (MIC50, 2 mg/L) was the most active compound, followed by imipenem (MIC50, 4 mg/L), cefepime (MIC50, 8 mg/L) end ceftazidime (MIC50, 16 mg/L). the results presented in this report confirm that bacterial resistance continues to be a great problem in Latin American medical institutions. |
publishDate |
2000 |
dc.date.issued.fl_str_mv |
2000-03-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T12:31:01Z |
dc.date.available.fl_str_mv |
2016-01-24T12:31:01Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Journal of Antimicrobial Chemotherapy. Oxford: Oxford Univ Press, v. 45, n. 3, p. 295-303, 2000. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/26254 http://dx.doi.org/10.1093/jac/45.3.295 |
dc.identifier.issn.none.fl_str_mv |
0305-7453 |
dc.identifier.doi.none.fl_str_mv |
10.1093/jac/45.3.295 |
dc.identifier.wos.none.fl_str_mv |
WOS:000086244100005 |
identifier_str_mv |
Journal of Antimicrobial Chemotherapy. Oxford: Oxford Univ Press, v. 45, n. 3, p. 295-303, 2000. 0305-7453 10.1093/jac/45.3.295 WOS:000086244100005 |
url |
http://repositorio.unifesp.br/handle/11600/26254 http://dx.doi.org/10.1093/jac/45.3.295 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Journal of Antimicrobial Chemotherapy |
dc.rights.driver.fl_str_mv |
http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
295-303 |
dc.publisher.none.fl_str_mv |
Oxford Univ Press |
publisher.none.fl_str_mv |
Oxford Univ Press |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1802764117288681472 |